Cat. No.: HY-B0356A

Ciprofloxacin monohydrochloride

(Synonyms: Bay-09867 monohydrochloride)

57 Cited Publications

Customer Review

Based on 57 publication(s) in Google Scholar

Ciprofloxacin (Bay-09867) monohydrochloride is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin monohydrochloride exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin monohydrochloride inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin monohydrochloride induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin monohydrochloride can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity.

For research use only. We do not sell to patients.

Purity: 99.86%
CAS No.: 93107-08-5
Formula: C₁₇H₁₉ClFN₃O₃
Molecular Weight:367.81

Storage:

4°C, sealed storage, away from moisture and light

* The compound is unstable in solutions, freshly prepared is recommended.

Ciprofloxacin monohydrochloride Chemical Structure

CAS No.: 93107-08-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (57)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Quinolone

All Antibiotic Isoforms :

All Topoisomerase Isoforms :

All Akt Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	135 μM Compound: 1	Inhibition of human A431 cell proliferation by MTT assay Inhibition of human A431 cell proliferation by MTT assay	[PMID: 19595598]
A-431	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
A-431	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
A549	IC₅₀	280 μM Compound: 1	Antitumor activity against human A549 cells after 5 days by MTT assay Antitumor activity against human A549 cells after 5 days by MTT assay	[PMID: 19595598]
A549	IC₅₀	>100 μM Compound: Ciprofloxacin	Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]
A549	IC₅₀	>302 nM Compound: Ciprofloxacin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30660827]
A549	IC₅₀	0.33 mM Compound: CFX	Antitumor activity against human A549 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay Antitumor activity against human A549 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay	[PMID: 31881454]
B-cell	IC₅₀	123 μM Compound: ciprofloxacin	Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs	[PMID: 19075064]
CAPAN-1	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
CHO	CC₅₀	512 μM Compound: CPFX	Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31525660]
CHO	IC₅₀	>150 μM Compound: CFX	Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability by MTT assay Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
CT26	IC₅₀	0.33 mM Compound: CFX	Antitumor activity against mouse CT26 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay Antitumor activity against mouse CT26 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay	[PMID: 31881454]
EJ	IC₅₀	202 μM Compound: 1	Inhibition of human EJ cell proliferation by MTT assay Inhibition of human EJ cell proliferation by MTT assay	[PMID: 19595598]
EJ	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
EJ	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
HaCaT	IC₅₀	222.1 μM Compound: CP	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
HBL-100	IC₅₀	10.28 μM Compound: C; Cip	Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34319100]
HEK-293T	CC₅₀	>60 μg/mL Compound: Ciprofloxacin	Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 27720324]
HeLa	IC₅₀	120 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	290 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	800 μM Compound: 1	Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
HeLa	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human HeLa cells after 24 hrs by LDH release assay Cytotoxicity against human HeLa cells after 24 hrs by LDH release assay	[PMID: 27018907]
Hep 3B2	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
HEp-2	CC₅₀	>100 μM Compound: CIP	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 17228862]
HEp-2	CC₅₀	>100 μM Compound: CIP	Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay	[PMID: 21425851]
HEp-2	CC₅₀	>100 μM Compound: CIP	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 21443219]
HepG2	CC₅₀	>100 μM Compound: CIP	Cytotoxicity against human HepG2 cells after 72 hrs Cytotoxicity against human HepG2 cells after 72 hrs	[PMID: 17228862]
HepG2	IC₅₀	>0.5 mM Compound: CPX, B-H	Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay	[PMID: 21855181]
HepG2	IC₅₀	>128 μg/mL Compound: CIP	Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay	[PMID: 27499455]
HepG2	IC₅₀	27 μM Compound: Ciprofloxacin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 28237557]
HepG2	CC₅₀	138.6 μg/mL Compound: CPX	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay	[PMID: 30067360]
HepG2	IC₅₀	>128 μg/mL Compound: CIP	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability for 24 hrs by Celltiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability for 24 hrs by Celltiter-Glo assay	[PMID: 35231579]
HL-60	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	>302 nM Compound: Ciprofloxacin	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	≥ 100 μM Compound: Ciprofloxacin	Antiproliferative activity against human HL60 cells by MTT assay Antiproliferative activity against human HL60 cells by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	>150 μM Compound: CFX	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
K562	IC₅₀	>150 μM Compound: 1	Inhibition of human K562 cell proliferation by sulphorodhamine B assay Inhibition of human K562 cell proliferation by sulphorodhamine B assay	[PMID: 19595598]
KB	IC₅₀	160 μM Compound: 1	Inhibition of human KB cell proliferation by MTT assay Inhibition of human KB cell proliferation by MTT assay	[PMID: 19595598]
KB	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
L02	IC₅₀	12.23 μM Compound: Ciprofloxacin	Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 35398730]
L02	IC₅₀	4.05 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 35398730]
L1210	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
L1210	IC₅₀	≥ 100 μM Compound: Ciprofloxacin	Antiproliferative activity against mouse L1210 cells by MTT assay Antiproliferative activity against mouse L1210 cells by MTT assay	[PMID: 30660827]
L1210	IC₅₀	>150 μM Compound: CFX	Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
L1210	IC₅₀	>150 μM Compound: CFX	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
L6	IC₅₀	3.3998 μM Compound: Ciprofloxacin Hydrochloride	Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay	[PMID: 32623216]
LoVo	IC₅₀	89 μM Compound: 1	Antitumor activity against human LoVo cells after 5 days by MTT assay Antitumor activity against human LoVo cells after 5 days by MTT assay	[PMID: 19595598]
MC3T3-E1	IC₅₀	120 μM Compound: 1	Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs	[PMID: 19595598]
MCF-10A	IC₅₀	>300 μM Compound: Ciprofloxacin	Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay	[PMID: 24513049]
MCF7	IC₅₀	199 μM Compound: 1	Inhibition of human MCF7 cell proliferation by MTT assay Inhibition of human MCF7 cell proliferation by MTT assay	[PMID: 19595598]
MCF7	IC₅₀	476 μM Compound: 1	Antitumor activity against human MCF7 cells after 5 days by MTT assay Antitumor activity against human MCF7 cells after 5 days by MTT assay	[PMID: 19595598]
MCF7	IC₅₀	76 μM Compound: 1	Inhibition of human MCF7 cell proliferation after 5 days by MTT assay Inhibition of human MCF7 cell proliferation after 5 days by MTT assay	[PMID: 19595598]
MCF7	CC₅₀	60 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 27720324]
MCF7	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
MCF7	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
MCF7	IC₅₀	8.85 μM Compound: C; Cip	Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34319100]
MG-63	IC₅₀	150 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	160 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	480 μM Compound: 1	Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
MRC5	IC₅₀	53.4 μg/mL Compound: CPF	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31431360]
MT4	CC₅₀	60 μM Compound: Ciprofloxacin	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 10397494]
NCI-H460	IC₅₀	60 μM Compound: 1	Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay	[PMID: 19595598]
NIH3T3	IC₅₀	>1000 μM Compound: 1	Inhibition of mouse NIH/3T3 cell proliferation by MTT assay Inhibition of mouse NIH/3T3 cell proliferation by MTT assay	[PMID: 19595598]
NIH3T3	IC₅₀	>200 μM Compound: Ciprofloxacin	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay	[PMID: 23711920]
NIH3T3	IC₅₀	305.77 μg/mL Compound: Ciprofloxacin	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay	[PMID: 28174104]
Osteoblast	IC₅₀	>400 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	170 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]
PBMC	IC₅₀	>0.5 mM Compound: CPX, B-H	Cytotoxicity against human PBMC measured after overnight incubation by MTT assay Cytotoxicity against human PBMC measured after overnight incubation by MTT assay	[PMID: 21855181]
PC-3	IC₅₀	143 μM Compound: 1	Antitumor activity against human PC3 cells after 5 days by MTT assay Antitumor activity against human PC3 cells after 5 days by MTT assay	[PMID: 19595598]
PC-3	IC₅₀	101.4 μM Compound: CP	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
SH-SY5Y	IC₅₀	>0.5 mM Compound: CPX, B-H	Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay	[PMID: 21855181]
SK-MEL	IC₅₀	196 μM Compound: 1	Inhibition of human SK-MEL cell proliferation by MTT assay Inhibition of human SK-MEL cell proliferation by MTT assay	[PMID: 19595598]
SK-MEL3	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SK-MEL3	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
SMMC-7721	IC₅₀	≥ 100 μM Compound: Ciprofloxacin	Antiproliferative activity against human SMMC7721 cells by MTT assay Antiproliferative activity against human SMMC7721 cells by MTT assay	[PMID: 30660827]
SMMC-7721	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
Splenocyte	IC₅₀	>40 μM Compound: CIPRO	Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method	[PMID: 19908867]
SW480	IC₅₀	128 μM Compound: 1	Inhibition of human SW480 cell proliferation by MTT assay Inhibition of human SW480 cell proliferation by MTT assay	[PMID: 19595598]
SW480	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SW480	IC₅₀	160.4 μM Compound: CP	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
SW480	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
SW-620	IC₅₀	200.4 μM Compound: CP	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
THP-1	IC₅₀	60.5 μM Compound: Ciprofloxacin	Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24650715]
U-373MG ATCC	IC₅₀	96 μM Compound: 1	Antitumor activity against human U373MG cells after 5 days by MTT assay Antitumor activity against human U373MG cells after 5 days by MTT assay	[PMID: 19595598]
V79	IC₅₀	>1000 μM Compound: 1	Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
Vero	IC₅₀	>188.5 μM Compound: Ciprofloxacin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19131245]
Vero	CC₅₀	600.8 μM Compound: CPFX	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat	[PMID: 21146257]
Vero	CC₅₀	128 μg/mL Compound: CPFX	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30025351]
Vero	CC₅₀	512 μg/mL Compound: CPFX	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30690301]
WI-38	IC₅₀	>100 μM Compound: Ciprofloxacin	Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]

In Vitro

Ciprofloxacin (2.5-10 μg/mL; 24-72 h) preserves the stem cell-like spindle morphology of immortalized human dermal papilla cells, and concentrations of 5 and 10 μg/mL for 72 h significantly increase cell aggregation size and number^[1].
Ciprofloxacin (10 μg/mL; 72 h) preserves CD133 stem cell marker expression and prevents increased procollagen type I fibroblast marker expression in immortalized human dermal papilla cells^[1].
Ciprofloxacin (10 μg/mL; 24-72 h) prevents time-dependent loss of CD133, integrin β1, and ALDH1A1 stem cell markers and increases in procollagen type I fibroblast marker in immortalized human dermal papilla cells; concentrations of 2.5-10 μg/mL for 72 h modulate these markers in a dose-dependent manner^[1].
Ciprofloxacin (2.5-10 μg/mL; 72 h) activates the Akt/GSK3β/β-catenin pathway in immortalized human dermal papilla cells in vitro in a dose-dependent manner, increasing activated Akt, inactivated GSK3β, and β-catenin levels^[1].
Ciprofloxacin (2.5-10 μg/mL; 72 h) activates the Akt/GSK3β/β-catenin pathway and upregulates EMT transcription factors (ZEB1, Snail) in primary human dermal papilla cells in vitro in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Tendon cells
Concentration:

5, 10, 20 and 50 μg/mL
Incubation Time:

24 hours
Result:

Decreased the cellularity of tendon cells.

Cell Cycle Analysis^[1]

Cell Line:

Tendon cells
Concentration:

50 μg/mL
Incubation Time:

24 hours
Result:

Arrested cell cycle at the G2/M phase and inhibited cell division in tendon cells.

Western Blot Analysis^[1]

Cell Line:

Tendon cells
Concentration:

50 μg/mL
Incubation Time:

0, 6, 12, 17 and 24 hours
Result:

Down-regulated the expression of CDK-1 and cyclin B protein and mRNA. Up-regulated the expression of PLK-1 protein.

In Vivo

Animal Model:

BALB/c mice^[3]
Dosage:

30 mg/kg
Administration:

Intraperitoneal injection; for 24 hours
Result:

Reduced the lung bacterial load in murine model of pneumonic plague.

Animal Model:

C57BL/6J mice^[4]
Dosage:

100 mg/kg
Administration:

Oral gavage; daily, for 4 weeks
Result:

Had aortic destruction that was accompanied by decreased LOX expression and increased MMP expression and activity.

Animal Model:

C57BL/6J mice^[4]
Dosage:

100 mg/kg
Administration:

Oral gavage; daily, for 4 weeks
Result:

Caused mitochondrial DNA and nuclear DNA damage, leading to mitochondrial dysfunction and ROS production. Increased apoptosis and necroptosis in the aortic wall.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 93107-08-5
Appearance Solid
Molecular Weight 367.81
Formula C₁₇H₁₉ClFN₃O₃
Color White to off-white
SMILES

[H]Cl.O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
Synonyms

Bay-09867 monohydrochloride
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (57)

All Bio/Physico-chemical AssayMicrobiological AssayOthers2D/3D Cell Culture and DifferentiationFlow Cytometry

Sort by:

Journal Impact Factor

Nature

Gut microbiota carcinogen metabolism causes distal tissue tumours. [Abstract]

2024 Aug;632(8027):1137-1144. PMID: 39085612
Mater Today

2026 Apr 7;96:103326.
Nat Cell Biol

Full-length GSDME mediates pyroptosis independent from cleavage. [Abstract]

2024 Sep;26(9):1545-1557. PMID: 38997456
Nat Commun

Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]

2022 Mar 2;13(1):1116. PMID: 35236849
Adv Sci (Weinh)

A Macromolecule Reversing Antibiotic Resistance Phenotype and Repurposing Drugs as Potent Antibiotics. [Abstract]

2020 Jul 21;7(17):2001374. PMID: 32995131
Water Res

Variable cyanobacterial death modes caused by ciprofloxacin in the aquatic environment: Prioritizing antibiotic-photosynthetic protein interactions for risk assessment. [Abstract]

2024 Nov 29:271:122885. PMID: 39642793

Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]

Ciprofloxacin (CIP, 3 or 8 μg/L, 0-7 days) caused concentration-dependent damage in M. aeruginosa cells.

Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]

Ciprofloxacin (CIP, 3 or 8 μg/L, 3 or 7 days) increased the release and decreased the biosynthesis of MC-LR in M. aeruginosa cells.

Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]

Ciprofloxacin (CIP, 8 μg/L, 1 day) enriched gene ontology terms related to PSI in M. aeruginosa cells.

Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]

Ciprofloxacin (CIP, 3 or 8 μg/L, 21 days) induced continuous cell lysis, with maximum lytic rates of ∼70% compared to the initial cell density.

Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885. [Abstract]

Ciprofloxacin (CIP, 3 or 8 μg/L, 1, 3, 5, or 7 days) induced cell death in M. aeruginosa.
Water Res

Quantifying community-wide antibiotic usage via urban water fingerprinting: Focus on contrasting resource settings in South Africa. [Abstract]

2023 Jul 15:240:120110. PMID: 37247434
Chem Eng J

2025 May 1.

Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 May 1.

The number of surviving bacteria after 24 h of treatment with free Ciprofloxacin monohydrochloride or Ciprofloxacin monohydrochloride-loaded liposomes at 658 a 3 μg/mL of Ciprofloxacin monohydrochloride concentration.

Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 May 1.

The CI values for 660 antibacterial efficacy of blank liposomes and Ciprofloxacin monohydrochloride.
J Exp Med

Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood. [Abstract]

2026 Mar 2;223(3):e20241287. PMID: 41400657
NPJ Biofilms Microbiomes

Echinacoside reduces intracellular c-di-GMP levels and potentiates tobramycin activity against Pseudomonas aeruginosa biofilm aggregates. [Abstract]

2025 Mar 7;11(1):40. PMID: 40055321
NPJ Biofilms Microbiomes

Gut microbiota dysbiosis-mediated ceramides elevation contributes to corticosterone-induced depression by impairing mitochondrial function. [Abstract]

2024 Oct 28;10(1):111. PMID: 39468065
EBioMedicine

A novel inhibitor of monooxygenase reversed the activity of tetracyclines against tet(X3)/tet(X4)-positive bacteria. [Abstract]

2022 Apr;78:103943. PMID: 35306337
Genome Biol

Caloric restriction remodels the hepatic chromatin landscape and bile acid metabolism by modulating the gut microbiota. [Abstract]

2023 Apr 30;24(1):98. PMID: 37122023
Food Res Int

Prevalence, plasmid transmission, and chromosomal integration of blaCTX-M genes in Salmonella isolated from retail chicken and pork meats in China. [Abstract]

2026 Aug 31:238:119421. PMID: 42215089
Emerg Contam

2026 Feb 23.
Arch Pharm Res

Cell membrane chromatography relative competitive method for the accurate determination of relative KD values of drug-receptor interactions. [Abstract]

2025 Jan;48(1):102-114. PMID: 39658753
J Med Chem

Design, Synthesis, and Biological Evaluation of Mono- and Diamino-Substituted Squaramide Derivatives as Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthase. [Abstract]

2025 Dec 11;68(23):25274-25289. PMID: 41277442
Virulence

Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]

2026 Dec 31;17(1):2646808. PMID: 41838520
Virulence

Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus. [Abstract]

2024 Dec;15(1):2415952. PMID: 39390774
J Agric Food Chem

Discovery of DNA Gyrase as a Promising Target against Phytopathogenic Bacteria. [Abstract]

2025 Dec 23. PMID: 41436099
Anal Chim Acta

A natural fluorescent protein for ciprofloxacin sensing and mechanism study using molecular docking and circular dichroism. [Abstract]

2022 Aug 15:1221:340082. PMID: 35934392
Front Microbiol

Enrofloxacin Promotes Plasmid-Mediated Conjugation Transfer of Fluoroquinolone-Resistance Gene qnrS. [Abstract]

2022 Feb 16:12:773664. PMID: 35250901
Colloids Surf A Physicochem Eng Asp

2025 Dec 26;734:139401.
Arab J Chem

2024 May, 17, 5, 105745.
ACS Appl Polym Mater

2023 Aug 29.

Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: ACS Appl Polym Mater. 2023 Aug 29.

Representative TEM images of blank micelles (BM) and Ciprofloxacin monohydrochloride-loaded micelles (CM) formulated in 1× PBS at pH 7.4.

Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: ACS Appl Polym Mater. 2023 Aug 29.

Cumulative ciprofloxacin release from Ciprofloxacin monohydrochloride-loaded micelles over 72 h with an inset of the release over the first 12 h at pH 4.4 (red) and pH 7.4 (gray).

Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: ACS Appl Polym Mater. 2023 Aug 29.

Cumulative Ciprofloxacin monohydrochloride release at 12 and 72 h.
Molecules

Assessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents. [Abstract]

2023 Jun 8;28(12):4628. PMID: 37375183
Int J Antimicrob Agents

Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. [Abstract]

2018 Aug;52(2):269-271. PMID: 29559273
PLoS Pathog

Differential contribution of PBP occupancy and efflux on the effectiveness of β-lactams at their target site in clinical isolates of Neisseria gonorrhoeae. [Abstract]

2024 Dec 31;20(12):e1012783. PMID: 39739989
Appl Microbiol Biotechnol

Anti-hepatitis C virus drug simeprevir: a promising antimicrobial agent against MRSA. [Abstract]

2022 Apr;106(7):2689-2702. PMID: 35338386
iScience

Analysis of microbiota reveals the underlying mechanism of PHF11 in the development of Enterococcus-regulated endometriotic cysts. [Abstract]

2023 Oct 7;26(11):108158. PMID: 37915596
Antimicrob Agents Chemother

Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae. [Abstract]

2026 Apr;70(4):e0170625. PMID: 41810969
Antimicrob Agents Chemother

An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]

2025 Jul 2;69(7):e0024925. PMID: 40407337
J Antimicrob Chemother

Harnessing metabolic dependence-driven antibiotic synergy to eradicate tolerant Pseudomonas aeruginosa. [Abstract]

2026 Jun 3;81(7):dkag204. PMID: 42267541
Microbiol Spectr

Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]

2025 Jul;13(7):e0307424. PMID: 40387379
Microbiol Spectr

Phenotypic and Genotypic Characterization of Multidrug-Resistant Enterobacter hormaechei Carrying qnrS Gene Isolated from Chicken Feed in China. [Abstract]

2022 Jun 29;10(3):e0251821. PMID: 35467399
Microbiol Spectr

The Mechanism of Action of Ginkgolic Acid (15:1) against Gram-Positive Bacteria Involves Cross Talk with Iron Homeostasis. [Abstract]

2022 Feb 23;10(1):e0099121. PMID: 35019708
J Antimicrob Chemother

In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. [Abstract]

2020 Jul 1;75(7):1850-1858. PMID: 32154866
Microb Pathog

Bacitracin-resistant Staphylococcus aureus induced in chicken gut and in vitro under bacitracin exposure. [Abstract]

2024 Jun:191:106666. PMID: 38685360
Appl Biochem Biotechnol

Evaluation of Benzothiazole-Chalcone Hybrids: Apoptosis Induction, Docking Analysis, and Anticancer Potential in Gastric Cancer Cells. [Abstract]

2025 Aug 23. PMID: 40848211
Water

2025 Jun 6.
Cardiovasc Toxicol

Ciprofloxacin Accelerates Angiotensin-II-Induced Vascular Smooth Muscle Cells Senescence Through Modulating AMPK/ROS pathway in Aortic Aneurysm and Dissection. [Abstract]

2024 Sep;24(9):889-903. PMID: 39138741
Infect Drug Resist

2026 May 8;19.
Infect Drug Resist

In vitro Activity of the Novel Tetracyclines Derivative, Zifanocycline Against Mycobacterium abscessus. [Abstract]

2025 Oct 4:18:5239-5247. PMID: 41069760
Eur J Clin Microbiol Infect Dis

Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants. [Abstract]

2025 Sep 29. PMID: 41023358
Anim Dis

Pasteurella multocida capsular: lipopolysaccharide types D:L6 and A:L3 remain to be the main epidemic genotypes of pigs in China. [Abstract]

2021;1(1):26. PMID: 34778886
Vet Microbiol

Discovery of the tigecycline resistance gene cluster tmexCD3-toprJ1 in Pasteurella multocida strains isolated from pigs in China. [Abstract]

2024 May:292:110046. PMID: 38471428
J Microbiol Methods

Comparison of agar-based and checkerboard methods to assess phage-antimicrobial synergy in Pseudomonas aeruginosa. [Abstract]

2026 Feb 25:107441. PMID: 41759663
Diagn Microbiol Infect Dis

A rapid bacterial labeling method for phenotypic antimicrobial susceptibility testing. [Abstract]

2026 Feb;114(2):117181. PMID: 41205476
bioRxiv

2026 Jan 19.
Orebro University

2024.
bioRxiv

2024 Nov 06.
bioRxiv

2024 May 10.
bioRxiv

2024 Feb 9.
bioRxiv

2024 Jan 18.
Research Square Preprint

2020 Jun.
Patent

US20200101105A1.
Chemosphere

Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]

2019 Jun:225:378-387. PMID: 30884299

Solvent & Solubility

In Vitro:

H₂O : 12.5 mg/mL (33.98 mM; Need ultrasonic)

DMSO : 5 mg/mL (13.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7188 mL

13.5940 mL

27.1880 mL

5 mM

0.5438 mL

2.7188 mL

5.4376 mL

10 mM

0.2719 mL

1.3594 mL

2.7188 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.5 mg/mL (1.36 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.5 mg/mL (1.36 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Kiratipaiboon C, et al. Ciprofloxacin Improves the Stemness of Human Dermal Papilla Cells. Stem Cells Int. 2016;2016:5831276. [Content Brief]

[2]. Li P, et al. In vivo and in vitro chondrotoxicity of ciprofloxacin in juvenile rats[J]. Acta Pharmacologica Sinica, 2004, 25: 1262-1266.

[3]. Kamocki K, et al. Effects of ciprofloxacin-containing antimicrobial scaffolds on dental pulp stem cell viability-In vitro studies. Arch Oral Biol. 2015;60(8):1131-1137. [Content Brief]

[4]. Ilgin S, et al. Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms. Toxicol Mech Methods. 2015;25(5):374-381. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	2.7188 mL	13.5940 mL	27.1880 mL	67.9699 mL
	5 mM	0.5438 mL	2.7188 mL	5.4376 mL	13.5940 mL
	10 mM	0.2719 mL	1.3594 mL	2.7188 mL	6.7970 mL
H₂O	15 mM	0.1813 mL	0.9063 mL	1.8125 mL	4.5313 mL
	20 mM	0.1359 mL	0.6797 mL	1.3594 mL	3.3985 mL
	25 mM	0.1088 mL	0.5438 mL	1.0875 mL	2.7188 mL
	30 mM	0.0906 mL	0.4531 mL	0.9063 mL	2.2657 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Ciprofloxacin monohydrochloride

57 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ciprofloxacin monohydrochloride

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Ciprofloxacin monohydrochloride

All Antibiotic Isoforms

All Topoisomerase Isoforms

All Akt Isoforms

Biological Activity

Chemical Information

Publications (57)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ciprofloxacin monohydrochloride

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Ciprofloxacin monohydrochloride

All Antibiotic Isoforms

All Topoisomerase Isoforms

All Akt Isoforms

Biological Activity

Chemical Information

Publications (57)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ciprofloxacin monohydrochloride Related Classifications

HY-B0356A Related Classifications